---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-24-000033"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:44:19.518416+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amgen Q2 2024 revenue up 20% to $8.4B, but GAAP EPS falls 46% to $1.38

## Summary
- Total revenues $8.4B, up 20% YoY; product sales up 20% (5% ex-Horizon), driven by 26% volume growth.
- GAAP EPS $1.38 (down 46%); non-GAAP EPS $4.97 (down 1%); GAAP operating margin 23.7% vs 40.2%.
- Free cash flow $2.2B, vs $3.8B in Q2 2023, due to timing of tax payments.
- Twelve products had double-digit sales growth; rare disease sales $1.1B; Repatha, Prolia, TEZSPIRE among leaders.
- Non-GAAP operating income $3.9B (up 11%); operating margin 48.2%, down 4.4pp year-over-year.

## SEC filing metadata
- accession: 0000318154-24-000033
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815424000033/0000318154-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815424000033/amgn-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-24-000033
- JSON: https://secwatch.observer/filing/0000318154-24-000033.json
- Plain text: https://secwatch.observer/filing/0000318154-24-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.